{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:06:12Z","timestamp":1793297172295,"version":"4.5.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australia National Health & Medical Research Council Investigator Grant","award":["2017661"],"award-info":[{"award-number":["2017661"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Outpatient parenteral antimicrobial therapy (OPAT) can deliver extended parenteral treatment of fungal infections in an ambulatory setting, whilst minimizing treatment burden and cost. The extended dosing interval of rezafungin may potentiate the benefits of OPAT.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective cohort study includes all adult patients who received echinocandin therapy in a large OPAT programme between 2012 and 2022. Patient characteristics, treatment and outcomes were studied. Data were analysed to determine the effects of replacing daily dosing with weekly dosing of echinocandin.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Across the study period, 11% (44\/386) of all patients in our Health Service treated with \u22657\u2005days of echinocandin were managed via OPAT. All were Candida and related \u2018yeast-like\u2019 species infections. Nakaseomyces glabrata (20\/41; 49%) was the most common pathogen, fungaemia the most common presentation (17\/41; 41%) and azole resistance the most frequent indication for echinocandin use (21\/41; 51%).<\/jats:p>\n In total, 633\u2005days of echinocandin were administered as OPAT. Thirteen patients (13\/41; 32%) received concurrent parenteral antibacterials. Treatment success was achieved in 30\/41 (73%) patients. If daily echinocandin dosing was replaced with weekly dosing, a potential 52% (633 to 326) reduction in the total number of treatments (for any therapy) delivered by the OPAT team is possible. The ongoing need for daily antibacterial administration mitigated the benefit in some of this cohort.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Echinocandin therapy can be safely delivered via OPAT with outcomes equivalent to bed-based care. The extended dosing interval of rezafungin will allow for a substantial reduction in the number of treatments required across the patient cohort.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jac\/dkae302","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:22:48Z","timestamp":1723634568000},"page":"2896-2900","source":"Crossref","is-referenced-by-count":4,"title":["Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by\n Candida<\/i>\n spp.: utilization, outcomes and impact of a change to weekly dosing"],"prefix":"10.1093","volume":"79","author":[{"given":"Fiona","family":"Clarke","sequence":"first","affiliation":[{"name":"Monash Infectious Diseases, Monash Health , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide","family":"Grenfell","sequence":"additional","affiliation":[{"name":"Monash Doctors, Monash Health , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chao","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Monash Health , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Richards","sequence":"additional","affiliation":[{"name":"Hospital in the Home, Monash Health , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Korman","sequence":"additional","affiliation":[{"name":"Monash Infectious Diseases, Monash Health , Clayton, Victoria ,","place":["Australia"]},{"name":"Department of Microbiology, Monash Health , Clayton, Victoria ,","place":["Australia"]},{"name":"Centre for Inflammatory Diseases, Monash University School of Clinical Sciences at Monash Health , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-2118","authenticated-orcid":false,"given":"Benjamin","family":"Rogers","sequence":"additional","affiliation":[{"name":"Monash Infectious Diseases, Monash Health , Clayton, Victoria ,","place":["Australia"]},{"name":"Hospital in the Home, Monash Health , Clayton, Victoria ,","place":["Australia"]},{"name":"Centre for Inflammatory Diseases, Monash University School of Clinical Sciences at Monash Health , Clayton, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"2024110323522249700_dkae302-B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/jof5030067","article-title":"Emerging fungal infections: new patients, new patterns, and new pathogens","volume":"5","author":"Friedman","year":"2019","journal-title":"J Fungi"},{"key":"2024110323522249700_dkae302-B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","article-title":"The changing epidemiology of invasive fungal infections","volume":"1508","author":"Enoch","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2024110323522249700_dkae302-B3","doi-asserted-by":"publisher","first-page":"e01876-20","DOI":"10.1128\/AAC.01876-20","article-title":"Experience with liposomal amphotericin B in outpatient parenteral antimicrobial therapy","volume":"65","author":"Burnett","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323522249700_dkae302-B4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.eimc.2020.01.019","article-title":"Antifungal treatment administered in OPAT programs is a safe and effective option in selected patients","volume":"38","author":"Gil-Navarro","year":"2020","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2024110323522249700_dkae302-B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","article-title":"Rezafungin (CD101), a next-generation echinocandin: a systematic literature review and assessment of possible place in therapy","volume":"14","author":"Sofjan","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2024110323522249700_dkae302-B6","doi-asserted-by":"publisher","first-page":"ofad505","DOI":"10.1093\/ofid\/ofad505","article-title":"Use of ceftriaxone and benzylpenicillin in outpatient parenteral antimicrobial therapy: spectrum versus cost","volume":"10","author":"Kalatharan","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024110323522249700_dkae302-B7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/imj.15213","article-title":"Observational study of the incidence and factors associated with patient readmission from home-based care under the Hospital in the Home programme","volume":"51","author":"Lim","year":"2021","journal-title":"Intern Med J"},{"key":"2024110323522249700_dkae302-B8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von Elm","year":"2007","journal-title":"Lancet"},{"key":"2024110323522249700_dkae302-B9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024110323522249700_dkae302-B10","doi-asserted-by":"publisher","first-page":"dlz026","DOI":"10.1093\/jacamr\/dlz026","article-title":"Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK","volume":"1","author":"Chapman","year":"2019","journal-title":"JAC Antimicrob Resist"},{"key":"2024110323522249700_dkae302-B11","author":"WHO"},{"key":"2024110323522249700_dkae302-B12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijantimicag.2017.05.019","article-title":"Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management","volume":"50","author":"Farmakiotis","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2024110323522249700_dkae302-B13","author":"Monash Health"},{"key":"2024110323522249700_dkae302-B14","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1128\/JCM.00308-13","article-title":"Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2024110323522249700_dkae302-B15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2024110323522249700_dkae302-B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2024110323522249700_dkae302-B17","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1182\/blood.V128.22.3396.3396","article-title":"Efficacy of CD101, a novel echinocandin, in prevention of pneumocystis pneumonia (PCP): thwarting the biphasic life cycle of pneumocystis","volume":"128","author":"Cushion","year":"2016","journal-title":"Blood"},{"key":"2024110323522249700_dkae302-B18","author":"Ong","year":"2017"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2896\/60271965\/dkae302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2896\/60271965\/dkae302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T18:52:31Z","timestamp":1730659951000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/11\/2896\/7755107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,11]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae302","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,11]]}}}